{
    "organizations": [],
    "uuid": "572050caae026d18b2cd6f47b6b9c9c3f2a3e76c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aeglea-bio-says-dosing-of-first-uv/brief-aeglea-bio-says-dosing-of-first-uveal-and-cutaneous-melanoma-patients-with-pegzilarginase-in-open-label-phase-1-cohort-expansions-idUSFWN1QQ0US",
    "ord_in_thread": 0,
    "title": "BRIEF-Aeglea Bio Says ‍Dosing Of First Uveal And Cutaneous Melanoma Patients With Pegzilarginase In Open-Label Phase 1 Cohort Expansions​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Aeglea Bio Therapeutics Inc:\n* AEGLEA BIO THERAPEUTICS - ‍DOSING OF FIRST UVEAL AND CUTANEOUS MELANOMA PATIENTS WITH PEGZILARGINASE IN OPEN-LABEL PHASE 1 COHORT EXPANSIONS​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T21:26:00.000+02:00",
    "crawled": "2018-03-09T14:20:55.080+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "aeglea",
        "bio",
        "therapeutic",
        "inc",
        "aeglea",
        "bio",
        "therapeutic",
        "first",
        "uveal",
        "cutaneous",
        "melanoma",
        "patient",
        "pegzilarginase",
        "phase",
        "cohort",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}